J&J myeloma drug shows 5-year remission in half of early-line patients

September 25, 2026 11:32 AM

Johnson & Johnson (NYSE: JNJ) reported that 50% of patients with relapsed or refractory multiple myeloma who received a single ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found